Effect of Dose Fractionation of Testosterone Cypionate on Transgender Men with Erythrocytosis

NACompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

November 18, 2024

Study Completion Date

December 17, 2024

Conditions
TestosteroneTranssexualismHematologic Diseases
Interventions
DRUG

Testosterone Cypionate 100 MG/ML

Testosterone is also responsible for increasing hematocrit by stimulating erythropoiesis (Velho et al., 2017). In cisgender men, who are hypogonadal and do not adequately produce testosterone, treatment with the use of testosterone is associated with stimulation of erythropoiesis, which can potentially increase blood viscosity, resulting in secondary erythrocytosis (Hajjar et al., 1997).

Trial Locations (1)

Unknown

Faculdade de Medicina de Ribeirão Preto - FMRP-USP, Ribeirão Preto

All Listed Sponsors
collaborator

Fundação de Amparo à Pesquisa do Estado de São Paulo

OTHER_GOV

lead

University of Sao Paulo

OTHER